Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR)-Reference-Cited by-同舟云学术

Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR)

Published:2023-01 Issue: Volume:245 Page:114886
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Zhang Na,Fan Tianyun^ORCID,Zhao Liping,Li Yiming,Bao Yunyang,Ma Xican,Mei Yuheng,Wang Yanxiang,Liu Yonghua,Deng Hongbin,Li Yinghong,He Hongwei,Song Danqing

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference35 articles.

1. Inhibition of MAP4K4 signaling initiaties metabolic reprogramming to protect hepatocytes from lipotoxic damage;Anand;J. Lipid Res.,2022

2. Mechanisms and disease consequences of nonalcoholic fatty liver disease;Loomba;Cell,2021

3. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: a systematic review and meta-analysis;Minich;EClinicalMedicine,2022

4. What's new in non-alcoholic fatty liver disease?;Spiers;Frontline Gastroenterol.,2022

5. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment;Yang;Eur. J. Med. Chem.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and evolution of berberine analogues as anti-Helicobacter pylori agents with multi-target mechanisms;Bioorganic Chemistry;2024-10

2. Isovalerylspiramycin I alleviates liver injury and liver fibrosis by targeting the nucleotide-binding protein 2 (NUBP2)-vascular non-inflammatory molecule-1 (VNN1) pathway;Journal of Pharmaceutical Analysis;2024-07

3. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02